(ALGS) Aligos Therapeutics - Ratings and Ratios

Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biopharmaceutical company, specializes in developing innovative treatments for viral and liver diseases. Their pipeline includes ALG-055009, a THR-β agonist in Phase 2a for NASH, targeting lipid metabolism. ALG-000184, a capsid assembly modulator, has completed Phase 1b for CHB, offering a novel approach to viral inhibition. ALG-125755, an siRNA candidate, is in Phase I for CHB, leveraging RNA interference for targeted therapy. ALG-097558, a protease inhibitor, is in Phase 2 for coronavirus, aligning with established antiviral strategies.

Strategic collaborations enhance Aligos capabilities: with Merck on oligonucleotides for NASH, Emory University for capsid modulators, Luxna Biotech for HBV-targeting oligonucleotides, and KU Leuven for coronavirus protease inhibitors. These partnerships underscore Aligos commitment to advancing therapeutic solutions through collaborative innovation.

3-Month Forecast: ALGS may face short-term weakness, trading below its 20 and 50-day SMAs, suggesting bearish momentum. However, the stock is supported by its position above the 200-day SMA, indicating long-term bullish potential. Pipeline advancements and collaborations could act as catalysts, potentially offsetting negative trends. The high ATR signals continued volatility, while the elevated P/S ratio reflects investor confidence in future growth despite current lack of profitability.